References
- Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol. 2019;3:77–103.
- Zahavi D, AlDeghaither D, O’Connell A, et al. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antibody Ther. 2018;1(1):7–12.
- Momeny M, Zarrinrad G, Moghaddaskho F, et al. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017 Jun 23;7(1):4204.
- Wu J, Mishra HK, Walcheck B. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy. J Leukoc Biol. 2019 Jun;105(6):1297–1303.
- Jing Y, Ni Z, Wu J, et al. Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One. 2015;10(3):e0121788.
- Srpan K, Ambrose A, Karampatzakis A, et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol. 2018 Sep 3;217(9):3267–3283.
- Saetersmoen ML, Hammer Q, Valamehr B, et al. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 2019 Jan;41(1):59–68.
- Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012 Jun 14;119(24):5640–5649.
- Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009 Apr 16;113(16):3716–3725.
- Dong C, Ptacek TS, Redden DT, et al. Fcgamma receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans. Arthritis Rheumatol. 2014 May;66(5):1291–1299.
- Arce Vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018 Apr 9;33(4):649–663 e4.
- Snyder KM, Hullsiek R, Mishra HK, et al. Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells. Front Immunol. 2018;9:2873.
- Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells [Review]. Blood. 2009 Oct 22;114(17):3513–3523.
- Dao T, Yan S, Veomett N, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013 Mar 13;5(176):176ra33.
- Raab S, Steinbacher J, Schmiedel BJ, et al. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J Immunol. 2014 Oct 15;193(8):4261–4272.
- van der Poel CE, Spaapen RM, van de Winkel JG, et al. Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol. 2011 Mar 1;186(5):2699–2704.
- Brandsma AM, Schwartz SL, Wester MJ, et al. Mechanisms of inside-out signaling of the high-affinity IgG receptor FcgammaRI. Sci Signal. 2018 Jul 24;11:540.
- Hogg N, Patzak I, Willenbrock F. The insider’s guide to leukocyte integrin signalling and function. Nat Rev Immunol. 2011 Jun;11(6):416–426.
- Zhao J, Lin Q, Song Y, et al. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018 Nov 27;11(1):132.